Business Wire

American Standard Leverages ExaGrid’s Scale-Out Architecture as Data Growth Nearly Triples Storage Requirements

Share

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that since 2009, ExaGrid has continued to provide American Standard with fast and reliable data backups and restores throughout the evolution of the company’s IT environment and substantial data growth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190206005141/en/

A subsidiary of LIXIL, American Standard has innovated and created residential and commercial produc ...

A subsidiary of LIXIL, American Standard has innovated and created residential and commercial products for kitchen and bath for over 140 years. (Photo: Business Wire)

A subsidiary of LIXIL, American Standard has innovated and created residential and commercial products for kitchen and bath for over 140 years.

American Standard has backed up its data to ExaGrid systems for nearly a decade, and ExaGrid has kept backups efficient and reliable throughout the evolution of American Standards’ IT environment and its major data growth resulting from the company becoming acquired by LIXIL Water Technology Americas (LWTA), a Tokyo-based global leader in housing and building materials, products, and services. “Since the acquisition, our data has grown almost 20% each year. LIXIL has continued to acquire other companies and their data has been migrated into our environment, resulting in significant data growth,” said Ted Green, American Standard’s lead information technology engineer.

ExaGrid’s data deduplication has maximized disk space and reduced rack space in American Standard’s data centers. “ExaGrid is very effective at reducing our backup storage footprint, allowing us to maximize disk space,” said Steve Pudimott, manager of IT services for American Standard. “We’ve always had one dedicated rack for ExaGrid. Now it has shrunk to half a rack at our production data center. That’s pretty significant, and it’s saved us on costs since we pay for power in our data center because it’s a colocation. Without deduplication, we’d probably need well over two racks by now, but we’ve been able to decrease from one rack to just half of a rack. The newer models of ExaGrid appliances are much smaller and shorter, so that has also helped us save on rack space, too,” added Green.

Recently, American Standard decided to virtualize its environment, shifting much of it over to VMware and installing Veeam to manage its virtual backups. ExaGrid integrates seamlessly with all of the most frequently used backup applications, including Veeam, which American Standard uses to back up its virtual environment, and Veritas NetBackup, which is used for the remaining physical servers. “At the time that we virtualized, our ExaGrid support engineer helped us configure our system to work with Veeam, and that was an easy process. When we installed Veritas NetBackup 16 recently on one of our servers, it took all of ten minutes to get it working with ExaGrid, and the ExaGrid plugin to work with NetBackup’s OST has been a great feature that has significantly sped up our backups,” said Green.

Since the initial installation of the first ExaGrid systems, Green has taken advantage of ExaGrid’s trade-in program, which allows customers to swap out older-model appliances for new ones at a discounted rate. “The capacity at both our production site and our disaster recovery (DR) site have doubled, if not tripled, since we first installed ExaGrid, so we have added appliances over the years. Working with ExaGrid’s sales and customer support teams is a major reason why we have continued to use ExaGrid for so many years.”

Read the complete American Standard customer success story to learn more about the company’s experience using ExaGrid.

ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivalled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’

About ExaGrid
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup.

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

Contact information

Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x0248

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu

Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX®▼ (daratumumab)19.7.2019 09:59:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the skin) use of DARZALEX® (daratumumab) for the treatment of patients with multiple myeloma. This subcutaneous formulation of daratumumab is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) [Halozyme's ENHANZE® drug delivery technology]. Daratumumab is currently only approved for intravenous (IV) use. “This new formulation is an example of our unwavering commitment to pursue innovative treatment options to support people living with multiple myeloma,” said Dr Patrick Laroche, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag. “Importantly, subcutaneous daratumumab demonstrated comparable efficacy with the existing IV formulation, reduced the rate of infusion-related reactions and significantly shortened the time it takes for patients to receive treatment, fr